Tristel

As an infection prevention business addressing a critical public health need, its mission is especially relevant to hospitals, where infection risks are highest. Tristel products support healthcare teams by providing highly effective disinfectants that eliminate a broad spectrum of harmful microorganisms and contribute to stronger infection-control practices.

The company is still in the early stages of its entry into the US healthcare market and, although there are plenty of growth opportunities in existing markets, Tristel’s future will be defined by strategic execution in the US.

Supporting growth of the core business, Tristel is developing new products, investing in its sales effort to drive product adoption and adapting its Cache strategy to target higher-value market segments. 

Tristel specialises in disinfection products for hospital settings, using chlorine dioxide to eliminate microorganisms such as E. coli, HIV, and Hepatitis. The nature of these products introduces risks around chemical handling and disposal, which could pose environmental and health hazards if not properly managed. Ensuring safe use and disposal is therefore important.

Some products are single-use and contain plastic, raising concerns about waste and environmental impact. While newer products incorporate more environmentally friendly materials, older items still contribute to plastic pollution.

Hazardous chemical waste and plastic disposal remain key environmental risks, making product design and end-of-life management important areas for improvement.